Last Price$213.6(1.4%)
Market Cap$375.8B
LTM Enterprise Value
$375.5B
5Y avg
$296.4B
Drug Manufacturers - General industry
median
$178.5B
Stock quality & Intrinsic value
6/10
0.4% undervalued
AbbVie Inc. Enterprise Value
Annual
Quarterly
LTM
Crunching data... Almost there!
| Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Enterprise Value | $50.1B | $89.4B | $112.6B | $119.1B | $129.1B | $182.6B | $168.0B | $159.5B | $265.3B | $309.5B | $343.6B | $321.1B | $375.5B |
Overvalued or undervalued?
Check the intrinsic value for ABBV
and see if it's the right time to invest.
AbbVie Inc. (ABBV) Enterprise Value comparison analysis
General
LTM Enterprise Value
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
AbbVie Inc.ABBV
$437.4B
3.7%
(11.4%)
7.6%
Median Peer Set
$249.1B
9.8%
11.0%
14.4%
Eli Lilly and CompanyLLY
$774.1B
32.0%
102.4%
23.5%
Johnson & JohnsonJNJ
$410.8B
4.3%
(57.9%)
15.8%
Novo Nordisk A/SNVO
$357.4B
24.9%
142.8%
34.8%
Merck & Co., Inc.MRK
$264.3B
6.7%
4,714.3%
26.7%
AstraZeneca PLCAZN
$257.0B
18.0%
18.9%
13.0%
Novartis AGNVS
$241.2B
10.8%
(16.5%)
23.1%
Amgen Inc.AMGN
$221.2B
18.6%
(39.8%)
12.2%
Pfizer Inc.PFE
$191.3B
8.8%
273.7%
12.6%
Gilead Sciences, Inc.GILD
$158.3B
6.0%
(91.6%)
1.7%
SanofiSNY
$157.6B
(3.8%)
3.1%
12.6%
ABBV key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 14,214.2 0.0% | 15,638.0 10.0% | 17,444.0 11.5% | 18,380.0 5.4% | 18,790.0 2.2% | 19,960.0 6.2% | 22,859.0 14.5% | 25,638.0 12.2% | 28,216.0 10.1% | 32,753.0 16.1% | 33,266.0 1.6% | 45,804.0 37.7% | 56,197.0 22.7% | 58,054.0 3.3% | 54,318.0 (6.4%) | 56,334.0 3.7% |
| Cost of Goods Sold (COGS) | 4,056.4 | 4,293.0 | 4,639.4 | 4,508.0 | 4,581.0 | 4,426.0 | 4,500.0 | 5,833.0 | 7,040.0 | 7,718.0 | 7,439.0 | 15,387.0 | 17,446.0 | 17,414.0 | 20,415.0 | 16,904.0 |
% margin | 10,157.8 71.5% | 11,345.0 72.5% | 12,804.6 73.4% | 13,872.0 75.5% | 14,209.0 75.6% | 15,534.0 77.8% | 18,359.0 80.3% | 19,805.0 77.2% | 21,176.0 75.0% | 25,035.0 76.4% | 25,827.0 77.6% | 30,417.0 66.4% | 38,751.0 69.0% | 40,640.0 70.0% | 33,903.0 62.4% | 39,430.0 70.0% |
| Operating Expenses | 5,056.0 | 6,315.0 | 8,511.3 | 7,767.0 | 8,207.0 | 11,771.0 | 10,672.0 | 10,221.0 | 11,257.0 | 18,228.0 | 12,459.0 | 17,856.0 | 19,865.0 | 21,826.0 | 21,146.0 | 30,293.0 |
| Research & Development Expenses (R&D) | 1,707.4 | 2,495.0 | 2,617.5 | 2,778.0 | 2,855.0 | 3,297.0 | 4,285.0 | 4,366.0 | 4,982.0 | 10,329.0 | 6,407.0 | 6,557.0 | 7,084.0 | 6,510.0 | 8,453.0 | 12,791.0 |
| Selling, General & Administrative Expenses (SG&A) | 3,348.6 | 3,820.0 | 5,893.8 | 4,989.0 | 5,352.0 | 7,724.0 | 6,387.0 | 5,855.0 | 6,275.0 | 7,399.0 | 6,942.0 | 11,299.0 | 12,349.0 | 15,260.0 | 12,872.0 | 14,752.0 |
% margin | 4,931.8 34.7% | 4,717.0 30.2% | 3,620.7 20.8% | 6,622.0 36.0% | 5,664.0 30.1% | 3,411.0 17.1% | 7,537.0 33.0% | 9,340.0 36.4% | 9,545.0 33.8% | 6,383.0 19.5% | 12,983.0 39.0% | 11,363.0 24.8% | 17,924.0 31.9% | 18,117.0 31.2% | 12,757.0 23.5% | 9,137.0 16.2% |
| Interest Income | 0.0 | 28.0 | 20.0 | 20.0 | 21.0 | 38.0 | 33.0 | 82.0 | 146.0 | 204.0 | 275.0 | 174.0 | 39.0 | 186.0 | 540.0 | 648.0 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 104.0 | 299.0 | 429.0 | 719.0 | 1,047.0 | 1,150.0 | 1,348.0 | 1,784.0 | 2,454.0 | 2,423.0 | 2,230.0 | 2,224.0 | 2,808.0 |
| Pre-tax Income | 5,950.3 | 4,836.0 | 3,668.5 | 5,725.0 | 5,332.0 | 2,369.0 | 6,645.0 | 7,884.0 | 7,727.0 | 5,197.0 | 8,426.0 | 3,398.0 | 12,989.0 | 13,477.0 | 6,250.0 | 3,716.0 |
% effective tax rate | 1,313.8 22.1% | 658.0 13.6% | 235.4 6.4% | 450.0 7.9% | 1,204.0 22.6% | 595.0 25.1% | 1,501.0 22.6% | 1,931.0 24.5% | 2,418.0 31.3% | 490.0 9.4% | 544.0 6.5% | 1,224.0 36.0% | 1,440.0 11.1% | 1,632.0 12.1% | 1,377.0 22.0% | (570.0) (15.3%) |
% margin | 4,636.5 32.6% | 4,178.0 26.7% | 3,433.1 19.7% | 5,275.0 28.7% | 4,128.0 22.0% | 1,774.0 8.9% | 5,144.0 22.5% | 5,953.0 23.2% | 5,309.0 18.8% | 5,687.0 17.4% | 7,882.0 23.7% | 4,616.0 10.1% | 11,542.0 20.5% | 11,836.0 20.4% | 4,863.0 9.0% | 4,278.0 7.6% |
| EPS | 2.87 | 2.59 | 2.12 | 3.35 | 2.58 | 1.11 | 3.15 | 3.65 | 3.31 | 3.69 | 5.30 | 2.73 | 6.48 | 6.65 | 2.73 | 2.42 |
| Diluted EPS | 2.85 | 2.57 | 2.11 | 3.35 | 2.56 | 1.10 | 3.13 | 3.63 | 3.30 | 3.68 | 5.28 | 2.72 | 6.45 | 6.63 | 2.72 | 2.41 |
% margin | 6,647.8 46.8% | 6,020.0 38.5% | 4,940.7 28.3% | 6,979.0 38.0% | 6,914.0 36.8% | 6,286.0 31.5% | 9,692.0 42.4% | 10,812.0 42.2% | 11,774.0 41.7% | 13,688.0 41.8% | 16,264.0 48.9% | 21,148.0 46.2% | 28,280.0 50.3% | 31,424.0 54.1% | 17,308.0 31.9% | 14,910.0 26.5% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is AbbVie Inc.'s Enterprise Value?
As of today, AbbVie Inc.'s last 12-month Enterprise Value is $375.5B, based on the financial report for Dec 30, 2024 (Q4’2024).
2) What is AbbVie Inc.'s Enterprise Value growth rate?
Over the last year, AbbVie Inc.'s Enterprise Value growth was 16.9%. The average annual Enterprise Value growth rates for AbbVie Inc. have been 11.0% over the past three years, 18.7% over the past five years.
3) Is AbbVie Inc.'s Enterprise Value growth rate Good?
Over the last year, AbbVie Inc.'s Enterprise Value growth was 16.9%, which is higher than industry growth of 0.0%. It indicates that AbbVie Inc.'s Enterprise Value growth is Good.